Cite
HARVARD Citation
Lapierre, L. et al. (2022). "Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies. Hematological oncology. 40 (4), pp. 805-808. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lapierre, L. et al. (2022). "Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies. Hematological oncology. 40 (4), pp. 805-808. [Online].